Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that FLT3 p.D835N status confers therapeutic sensitivity to Cytarabine, Daunorubicin, Midostaurin in patients with Acute Myeloid Leukemia.
This statement is based on a regulatory approval from the Health Canada:
RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).